Dalton Leads International Team Developing Novel Vaccines

Share Article

Dalton awarded funding from ISTPCanada as part of an international vaccine development project under the 2013 Canada-China Joint Initiative on Human Vaccine Research and Development program

“This international collaborative approach will accelerate the development of these vaccines”

Dalton Pharma Services, a privately owned pharmaceutical services provider, today announced that they were awarded funding from ISTPCanada as part of an international vaccine development project under the 2013 Canada-China Joint Initiative on Human Vaccine Research and Development program. The international team represents leaders in both academic and industrial vaccine development including the Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO-InterVac), the Pan-Provincial Vaccine Enterprise Inc. (PREVENT), the South China United Vaccine Institute and the Guangzhou Institute of Respiratory Disease. Additional funding was awarded to VIDO-InterVac through Canadian Institutes of Health Research and the Chinese partners through the Chinese Ministry of Science and Technology.

The goal of the project is to complete the pre-clinical development of the world’s first vaccines for respiratory syncytial virus (RSV) and parainfluenza type 3 (PIV3) virus, and ultimately a co-formulated combination vaccine. The project leverages a novel adjuvant which is designed to induce a powerful balanced immune response against a variety of viral and bacterial antigens. The development of vaccines against the two viruses would result in a significant health impact for Canada, China and the rest of the world, with over 800 million of the young and aged citizens especially at risk from these viruses.

Dr. Andrew Potter, Director and CEO of VIDO-InterVac and PREVENT commented, “This project has brought together the complementary expertise of leading Canadian and Chinese organizations in their respective fields. This international collaborative approach will accelerate the development of these vaccines.”

Peter Pekos, President and CEO of Dalton, said, “We are very pleased that Dalton’s many years of experience in the development of components for novel vaccines will be utilized along with the international experts assembled on this team towards improving public health around the world.”

About Dalton:
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Canadian cGMP contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and aseptic filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its modern cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts aseptic fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients. http://www.dalton.com

For further information contact:
Peter Pekos
Dalton Pharma Services

International Science and Technology Partnerships Canada (ISTPCanada) facilitates the creation of global technology partnerships that open new markets and trade doors for Canadian companies. ISTPCanada develops and implements R&D collaboration programs under Science and Technology (S&T) cooperation agreements between Canada and three key trade partners: Brazil, China and India. Mandated by the Government of Canada through Foreign Affairs, Trade and International Canada (DFATD), ISTPCanada facilitates R&D cooperation between Canadian companies, research organizations and their counterparts in these countries; and invests in collaborative R&D projects. All S&T partnerships facilitated by ISTPCanada are jointly financed by industry, foreign partners, and often provincial governments. Since its inception in 2007, ISTPCanada has facilitated hundreds of S&T collaborations and gained almost four-fold leverage on every dollar invested by the Government of Canada. Moreover, these technology partnerships increase the competitiveness of companies as they acquire knowledge, customers and opportunities that facilitate access to new global markets. The resulting commercial activity generates increased trade, new jobs and wealth creation in Canada. For additional information, please visit: http://www.istpcanada.ca.

About VIDO-InterVac (Vaccine and Infectious Disease Organization - International Vaccine Centre)
Created in 1975, VIDO‐InterVac is a research organization of the University of Saskatchewan with financial support from the Government of Canada, Government of Saskatchewan, various foundations, corporations and producer groups. With some of the world’s most advanced containment Level two and three facilities, as well as a 160‐acre research station, VIDO‐InterVac develops new approaches to infectious disease threats. VIDO-InterVac has developed eight commercial vaccines employs over 150 scientists/technicians and works with public and private sector partners in more than 20 countries.

About PREVENT (Pan-Provincial Vaccine Enterprise Inc.)
An incorporated not-for-profit organization, PREVENT is accelerating the development of promising early-stage vaccine candidates to address existing or potential human health issues. PREVENT’s founding members include: the Vaccine and Infectious Disease Organization – International Vaccine Centre (VIDO-InterVac), the BC Centre for Disease Control (BC-CDC), and the Canadian Center for Vaccinology (CCfV) at Dalhousie University. By partnering with Canadian experts and shouldering the risk of early-stage vaccine development, PREVENT strengthens and advances Canada’s vaccine industry, promoting growth and improved global competitiveness.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Peter Pekos
Visit website